CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
glofitamab 治疗后复发，一种新出现的未满足医疗需求，伴有高比例的 CD20 丢失
英文原题：Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
查看英文原题
Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年，由于T细胞激活疗法的引入，r/r DLBCL的预后已发生实质性改变。除了为一部分r/r DLBCL带来新的治愈前景外，CAR-T 细胞疗法和双特异性抗体也正在产生新的未满足需求。Grigg及其同事的报告现在表明，glofitamab难治性、CD20阴性患者代表了一种新的未满足医疗需求，需要CD20以外的治疗靶点以及新型疗法来降低CD20丢失的风险。评论：Grigg等。glofitamab后复发预后差，且CD20丢失率高。Br J Haematol 2024;205:122-126。
展开英文摘要原文
The prognosis of r/r DLBCL has changed substantially over the past decade due to the introduction of T-cell-activating therapies. Besides generating a new curative perspective for a proportion of r/r DLBCL, chimeric antigen receptor T-cell therapy and bispecific antibodies are generating new unmet needs.
The report by Grigg and colleagues now shows that glofitamab-refractory, CD20-negative patients represent a new unmet medical need requiring therapeutic targets other than CD20 and novel therapies to reduce the risk of CD20 loss. Commentary on: Grigg et al. Relapse after glofitamab has a poor prognosis, and rates of CD20 loss are high. Br J Haematol 2024;205:122-126.
论文信息
- 作者
- Carlo-Stella C
- 单位
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.Italy
- 期刊
- British journal of haematology2024 Jul
- 原文标识
- PubMed 38813657 · DOI 10.1111/bjh.19503